Emerging drugs for ocular allergy

Bibliography

• ABELSON MB: Allergic disease of the eye. MB Abelson (Ed.), WB Saunders Co, Philadelphia, USA (2001).
   Google Scholar
• KAY AB: Allergy and allergic diseases. Part I. N EngL J. Med. (2001) 344:30–37.
   PubMed Web of Science ®Google Scholar
• TODA M, ONO SJ: Genomics and proteomics of allergic disease. Immunology (2002) 106:1–10.
   PubMed Web of Science ®Google Scholar
• •Review on genetics for ocular allergy.
   Google Scholar
• MCGILL JI, HOLGATE ST, CHURCH MK, ANDERSON DF, BACON A: Allergic eye disease mechanisms. Br. J. OphthalmoL (1998) 82:1203–1214.
   PubMed Web of Science ®Google Scholar
• TAKENAKA H, ZHANG K,DIAZ-SANCHEZ D, TSEIN A, SACKSON A: Enhanced human IgE production results from exposure to the aromatic hydocarbons from diesel exhaust: direct effects on B cell IgE production. J. Allergy Clin. Immunol. (1995) 95:103–115.
   PubMed Web of Science ®Google Scholar
• LEONARDI k Vernal keratoconjunctivitis: pathogenesis and tratment. Prog. Ret. Eye Res. (2002) 21:319–339.
   PubMed Web of Science ®Google Scholar
• CALDER VL, JOLLY G, HINGORANI M et al.: Cytokine production and mRNA expression by conjunctival T cell lines in chronic allergic eye diseases. Clin. Exp. Allergy (1999) 29:1214–1222.
   PubMed Web of Science ®Google Scholar
• MONTAN PG, SCHEYNIUS A. VAN DER PLOEG I: Similar T helper Th2-like cytokine mRNA expression in vernal keratoconjunctivitis regardless of atopic constitution. Allergy (2002) 57:436–441.
   PubMed Web of Science ®Google Scholar
• FOSTER CS, CALONGE M: Atopic keratoconjunctiuvitis. Ophthalmology (1990) 97:992–100.
   PubMed Web of Science ®Google Scholar
• FOSTER CS, RICE BA, DUTT JE: Immunopathology of atopic keratoconjunctivitis. Ophthalmology (1991) 98:1190–1196.
   PubMed Web of Science ®Google Scholar
• TUFT SJ, KEMENY DM, DART JK, BUCKLEY RJ: Clinical features of atopic keratoconjunctivitis. Ophthalmology (1991) 98:150–158.
   PubMed Web of Science ®Google Scholar
• ALLANSMITH MR, KORB DR, GREINER JV et al.: Giant papillary conjunctivitis in contact lens wearers. Am. J. Ophthalmol. (1977) 83:697–708.
   PubMed Web of Science ®Google Scholar
• ALLANSMITH MR, KORB DR, GREINER JV: Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology (1978) 85:766–778.
   PubMed Web of Science ®Google Scholar
• IRKEC MT, ORHAN M, ERDENER U: Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. OcuL Immunol. Infiamm. (1999) 7:35–38.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: Biology of human Thland Th2 cells. J. Clin. Immunol. (1995) 15:121–129.
   PubMed Web of Science ®Google Scholar
• BONINI S, BONINI S, BUCCI MG et al.:Allergen dose response and late symptoms in a human model of ocular allergy. J. Allergy Clin. Immunol. (1990) 86:869–876.
   PubMed Web of Science ®Google Scholar
• LEONARDI AA, SMITH LM, FREGONA IA, SALMASO M, SECCHI AG: Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide. Eur. j OphthalmoL (1996) 6: 106–112.
   Google Scholar
• BACON AS, AHLUWALIA P, IRANI AM et al.: Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. (2000) 106:948–954.
   PubMed Web of Science ®Google Scholar
• ONO SJ, ABELSON MB: Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. (2005) 115:118–122.
   PubMed Web of Science ®Google Scholar
• MACLEOD JDA, ANDERSON DF, BADDELEY SM, HOLGATE ST, MCGILL JI, ROCHE WR: Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. Clin. Exp. Allergy (1997) 27:1328–1334.
   PubMed Web of Science ®Google Scholar
• IRANI AA, BUTRUS SI, TABBARA KF, SCHWARTZ LB: Human conjunctival mast cells: distribution of MCT and MCTC cells in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. (1990) 86:34–39.
   PubMed Web of Science ®Google Scholar
• ANDERSON DF, ZHANG S, BRADDING P et al.: The relative contribution of mast cell subsets to conjunctival T(H)2-like cytokines. Invest. OphthalmoL Vis. Sci. (2001) 42:995–1001.
   PubMed Web of Science ®Google Scholar
• MILLERS, COOK EB, GRAZIANO FM et al.: Human conjunctival mast cell responses in vitro to various secretagogues. OcuL Immunol. Infiamm. (1996) 4:39–49.
   PubMed Web of Science ®Google Scholar
• COOK EB, STAHL J, MILLERS et al.: Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-alpha from mast cells affects intercellular adhesion molecule-1 expression on epithelial cells. Invest. OphthalmoL Vis. Sci. (1998) 39:336–343.
   PubMed Web of Science ®Google Scholar
• TROCME SD, ALDAVE AJ: The eye andthe eosinophil. Survey Ophthalmol (1994) 39:241–252.
   PubMed Web of Science ®Google Scholar
• TROCME SD, LEIFERMAN KM, GEORGE T et al.: Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis. Curr. Eye Res. (2003) 26:319–325.
   PubMed Web of Science ®Google Scholar
• METZ DP, BACON AS, HOLGATE S, LIGHTMAN SL: Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J. Allergy Clin. Immunol. (1996) 98:686–696.
   PubMed Web of Science ®Google Scholar
• METZ DP, HINGORANI M, CALDER VL, BUCKLEY RJ, LIGHTMAN SL: T cell cytokines in chronic allergic eye diseases. J. Allergy Clin. Immunol. (1998) 100:817–824.
   Web of Science ®Google Scholar
• ZHAN H, CALDER V LIGHTMAN S: T-cell characterization in chronic allergic eye disease. Curr. Allergy Asthma Rep. (2003) 3:358–362.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, SCHAEFER K, WUN PJ: Antihistamines and antihistamine/ vasoconstrictor combinations. In: Allergic diseases of the eye. MB Abelson (Ed.), WB Saunders Co, Philadelphia, USA (2001):206–214.
   Google Scholar
• DECHANT KL, GOA KL: Levocabastine:a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs (1991) 41: 202–224.
   Google Scholar
• ABELSON MB, GEORGE MA, SCHAEFER K, SMITH LM: Evaluation of the new ophthalmic antihistamine 0.05% levocabastine in the clinical allergen challenge model of allergic conjunctivitis. J. Allergy Clin. Immunol. (1994) 94:458–464.
   PubMed Web of Science ®Google Scholar
• SECCHI A, LEONARDI A. DISCEPOLA M et al.: An efficacy and tolerance comparison of emedastine difumarate 0.5% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Acta OphthalmoL Scand. (2000) 78(230):48–51.
   Google Scholar
• SECCHI A, CIPRANDI G, LEONARDI A et al.: Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Acta Ophthalmol. Scand. (2000) 78(230):42–47.
   PubMedGoogle Scholar
• YANNI JM, SHARIF NA, GAMACHE DA et al.: A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol. (1999) 77(228):33–37.
   Google Scholar
• LEONARDI A, DEFRANCHIS G, DEPAOLI M, FREGONA IA, PLEBANI M, SECCHI AG: Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts. Curr. Eye Res. (2002) 25:189–196.
   PubMed Web of Science ®Google Scholar
• BIELORY L, LIEN KW, BIGELSEN S: Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs (2005) 65(2):215–228.
   PubMed Web of Science ®Google Scholar
• •Review on mechanisms of actions of topical and systemic antihistamines for ocular allergy.
   Google Scholar
• ABELSON MB, WELCH DL: An evaluation of onset and duration of action of Patanol® (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Clarkin® (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol. Scand. (2000) 78(230):60–63.
   Google Scholar
• COOK EB, STAHL JL, BARNEY NP, GRAZIANO FM: Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr. Drug Targets Inflamm. Allergy (2002) 1(2):167–180.
   PubMedGoogle Scholar
• •Review on mechanisms of actions of topical antiallergic drugs.
   Google Scholar
• KAZDAN JJ, CRAWFORD JS, LANGER H, MACDONALD AL: Sodium cromoglycate (Intal) in the treatment of vernal keratoconjunctivitis and allergic conjunctivitis. Canad. J. Ophthalmol. (1976) 11:300–303.
   PubMed Web of Science ®Google Scholar
• FOSTER CS, DUNCAN J: Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis. Am. J. Ophthamol. (1980) 90:175–181.
   PubMed Web of Science ®Google Scholar
• MONTAN P, ZETTERSTROM O, STROMQUIST L-H: Topical sodium cromoglycate (Opticrom) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes. Allergy (1994) 49:637–640.
   PubMed Web of Science ®Google Scholar
• FROSTAD AB, OLSEN AK: A comparisonof topical levocabastine and sodium cromoglycate in the treatment of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis. Clin. Exp. Allergy (1993) 23:406–409.
   PubMed Web of Science ®Google Scholar
• LEINO M, MONTAN P, NJAA F: A double-blind group comparison study of ophthalmic sodium cromoglycate 2% four times daily and 4% twice daily in the treatment of seasonal allergic conjunctivitis. Allergy (1994) 49:147–151.
   PubMed Web of Science ®Google Scholar
• YANNI JM, MILLER ST, GAMACHE DA. SPELLMAN JM, XU S, SHARIF NA: Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol. (1997) 79:541–545.
   PubMed Web of Science ®Google Scholar
• •Shows the inhibition of histamine release of different antiallergic drugs on conjunctival mast cell cultures.
   Google Scholar
• CALONGE M, MONTERO JA, HERRERAS JM et al.: Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann. Allergy Asthma Immunol. (1996) 77:124–130.
   PubMed Web of Science ®Google Scholar
• BLUMENTHAL M, CASALE T, DOCKHORN R et al.: Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am. J. Ophthalmol. (1992) 113:56–63.
   PubMed Web of Science ®Google Scholar
• KJELLMAN MN-I, STEVENS MT: Clinical experience with Tilavist: an overview of efficacy and safety. Allergy (1995) 50(Suppl. 21):14–22.
   PubMed Web of Science ®Google Scholar
• LEONARDI A. BORGHESAN F, AVARELLO A, PLEBANI M, SECCHI AG: Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br. J. Ophthalmol. (1997) 81:23–26.
   PubMed Web of Science ®Google Scholar
• SANTOS CI, HUANG AJ, ABELSON MB et al.: Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am. J. Ophthalmol. (1994) 117:488–497.
   PubMed Web of Science ®Google Scholar
• CALDWELL DR, VERIN P, HARTWICH-YOUNG R et al.: Efficacy and safety of lodoxamide 0.1% versus cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am. J. Ophthalmol. (1992) 113:632–637.
   PubMed Web of Science ®Google Scholar
• GUNDUZ K, UCAKHAN O, BUDAK K, ERYILMAZ T, OZKAN M: Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis. Ophthalmic Res. (1996) 28:80–87.
   PubMed Web of Science ®Google Scholar
• CERQUETI PM, RICCA V, TOSCA MA et al.: Lodoxamide treatment of allergic conjunctivitis. Int. Arch. Allergy Immunol. (1994) 105:185–189.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, BERDY GJ, MUNDORF T, AMDAHL LD, GRAVES AL: Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, Phase III studies. Ocul. Pharmacol. Ther. (2002) 18:475–488.
   PubMed Web of Science ®Google Scholar
• GOUS P, ROPO k A comparative trial ofthe safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis./ Ocul. Pharmacol. Ther. (2004) 20:139–150.
   Google Scholar
• DENTS D, BLOCH-MICHEL E, VERIN P et al.: Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA. Br. J. Ophthalmol. (1998) 82:1135–1138.
   PubMed Web of Science ®Google Scholar
• BOUHLAL H, BLONDIN C, HAEFFNER-CAVAILLON N, GOLDSCHMIDT P: Nacetyl-aspartyl glutamic acid (NAAGA) inhibits the adhesion of leukocytes to activated endothelial cells and down-modulates the cytokine-induced expression of adhesion molecules. J. Fr. Opthalmol. (2002) 25:993–1000.
   PubMed Web of Science ®Google Scholar
• ABELSON MB: A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother. (2004) 5:1979–1994.
   PubMed Web of Science ®Google Scholar
• COOK EB, STAHL JL, BARNEY NP, GRAZIANO FM: Olopatadine inhibits TNF-alpha release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. (2000) 84:504–508.
   PubMed Web of Science ®Google Scholar
• COOK EB, STAHL JL, BARNEY NP, GRAZIANO FM: Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. (2001) 87:424–429.
   PubMed Web of Science ®Google Scholar
• COOK EB, STAHL JL, BARNEY NP, GRAZIANO FM: The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Ann. Allergy Asthma ImmunoL (2004) 92:65–72.
   PubMed Web of Science ®Google Scholar
• YANNI JM, STEPHENS DJ, MILLER ST et al.: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A) and effective anti-allergic/anti-histaminic agent. J. Ocular Pharmacol. (1996) 12:389–400.
   Google Scholar
• LEONARDI A, ABELSON MB: Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. (2003) 25:2539–2552.
   PubMed Web of Science ®Google Scholar
• AGUILAR AJ: Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta OphthalmoL Scand. (2000) 78(Suppl. 230):52–55.
   Google Scholar
• LEONARDI A, ZAFIRAKIS P: Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr. Med. Res. Opin. (2004) 20:1167–1173.
   PubMed Web of Science ®Google Scholar
• BUTRUS S, GREINER JV, DISCEPOLA M, FINEGOLD I: Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. (2000) 22:1462–1472.
   PubMed Web of Science ®Google Scholar
• DESCHENES J, DISCEPOLA M, ABELSON MB: Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta OphthalmoL Scand. (1999) 77(228):47–52.
   Google Scholar
• GRANT SM, GOA KL, FITTON k SORKIN EM: Ketotifen: a review of its pharmacodynamic and pharmakinetic properties, and therapeutic use in asthma and allergic disorders. Drugs (1990) 40:412–448.
   PubMed Web of Science ®Google Scholar
• CRAMPTON HJ: A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin. Ther. (2002) 24:1800–1808.
   PubMed Web of Science ®Google Scholar
• GREINER JV, MICHAELSON C, MCWHIRTER CL, SHAMS NB: Single dose of ketotifen fumarate.025% versus 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv. Ther. (2002) 19:185–193.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, FERZOLA NJ, MCWHIRTER CL, CRAMPTON HJ: Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr. Allergy ImmunoL (2004) 15:551–557.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, BUSCAGLIA S, CATRULLO A et al.: Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin. Exp. Allergy (1997) 27:182–191.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER MH, HARRIS J, LAVALLEE N et al.: Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology (2000) 107:2152–2157.
   PubMed Web of Science ®Google Scholar
• LENHARD G, MIVSEK-MUSIC E, PERRIN-FAYOLLE M et al.: Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Curr. Med. Res. Opin. (1997) 14:21–28.
   PubMed Web of Science ®Google Scholar
• SABBAH A. MARZETTO M: Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr. Med. Res. Opin. (1998) 14:161–170.
   PubMed Web of Science ®Google Scholar
• GIEDE C, METZENAUER P, PETZOLD U, ELLERS-LENZ B: Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr. Med. Res. Opin. (2000) 16:153–163.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW: Epinastine hydrochloride for atopic disease. Drugs Today (2004) 40:677–683.
   PubMed Web of Science ®Google Scholar
• TASAKA K: Epinastine: an update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today (2000) 36:735–757.
   PubMed Web of Science ®Google Scholar
• MATSUKURA M, YAJIMA A. YAMAZAKI F, YUDATE T, YAIVIADA H, TEZUKA T: Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin PharmacoL Appl. Skin PhysioL (2003) 16:405–410.
   PubMedGoogle Scholar
• ABELSON MB, GOMES P, CRAMPTON HJ, SCHIFFMAN RM, BRADFORD RR, WHITCUP SM: Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin. Ther. (2004) 26:35–47.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, BRADFORD R, LUE J, SCHIFFMAN RM, ABELSON MB: Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin. Ther. (2004) 26:29–34.
   PubMed Web of Science ®Google Scholar
• BALLAS Z, BLUMENTHAL M, TINKELMAN DG et al.: Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv. OphthalmoL (1993) 38(Suppl.):141–148.
   PubMed Web of Science ®Google Scholar
• TINKELMAN D, RUPP G, KAUFMAN H et al.: Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of seasonal allergic conjunctivitis: a placebo-controlled clinical trial. Surv. OphthalmoL (1993) 38(Suppl.):133–140.
   PubMed Web of Science ®Google Scholar
• TAUBER J, RAIZMAN MB, OSTROV CS et al.: A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J. OcuL PharmacoL Ther. (1998) 14:137–145.
   PubMed Web of Science ®Google Scholar
• D'ANGELO G, LAMBIASE A, CORTES M et al.: Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graves Arch. Clin. Exp. OphthalmoL (2003) 241:192–195.
   PubMed Web of Science ®Google Scholar
• TABBARA KF, AL-KHARASHI SA: Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br. J. OphthalmoL (1999) 83:180–184.
   PubMed Web of Science ®Google Scholar
• DELL SJ, LOWRY GM, NORTHCUTT JA et al.: A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J. Allergy Clin. ImmunoL (1998) 102:251–255.
   PubMed Web of Science ®Google Scholar
• ABELSON M, HOWES J, GEORGE M: The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. Ocul. PharmacoL Ther. (1998) 14:533–542.
   PubMed Web of Science ®Google Scholar
• BARTLETT JD, HOWES JF, CHORMLEY NR et al.: Safety and efficacy
   Google Scholar
• •• of loteprednol etabonate for treatment of papillae in contact lens associated giant papillary conjunctivitis. Curr. Eye Res. (1993) 12:313–321.
   PubMed Web of Science ®Google Scholar
• LEONARDI A, PAPA V, MILAZZO G, SECCHI AG: Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea (2002) 21:476–481.
   PubMed Web of Science ®Google Scholar
• BUNDOC VG, KEANE-MYERS A: Animal models of ocular allergy Curr. Opin. Allergy Clin. ImmunoL (2003) 3:375–379.
   PubMedGoogle Scholar
• MIYAZAKI D, NAKAMURA T, TODA M, CHEUNG-CHAU KW, RICHARDSON RM, ONO SJ: Macrophage inflammatory protein-1 alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest. (2005) 115:434–442.
   PubMed Web of Science ®Google Scholar
• ••New possible mechanisms of actions ofchemokines as costimulatory signal necessary for mast cell activation and degranulation.
   Google Scholar
• KEANE-MYERS AM, MIYAZAKI D, LIU G, DEKARIS I, ONO S, DANA MR: Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest. OphthalmoL Vis. Sci. (1999) 40:3041–3046.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI D, LIU G, CLARK L, ONO SJ: Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. OphthalmoL Vis. Sci. (2000) 41:3850–3855.
   PubMed Web of Science ®Google Scholar
• •New approach in the animal model for the treatment of ocular allergy with immunostimulatory DNA sequences.
   Google Scholar
• LEONARDI A, CORTIVO R, FREGONA I, PLEBANI M, SECCHI AG, ABATANGELO G: Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts. Invest. OphthalmoL Vis. (2003) 44:183–189.
   PubMed Web of Science ®Google Scholar
• LEONARDI A. BRUN P, SARTORI MT et al.: Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Invest. OphthalmoL Vis. Sci. (2005) 46:1364–1370.
   PubMed Web of Science ®Google Scholar
• LEONARDI A. BRUN P, ABATANGELO G, PLEBANI M, SECCHI AG: Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest. OphthalmoL Vis. Sci. (2003) 44:3052–3058.
   PubMed Web of Science ®Google Scholar
• •Evidence that MMPs play a significant role in the pathogenesis of VKC.
   Google Scholar
• ABELSON MB, GOMES PJ, VOGELSON CT et al.: Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin. Ther. (2004) 26:1237–1248.
   PubMed Web of Science ®Google Scholar
• GARCIA E, PAU A, GISPERT J, RIGA A et al.: Carebastine eye drops in the management of seasonal allergic conjunctivtis (SAC). J. Allergy Clin. Immunol (1998) 101:1 Pt 2.
   Google Scholar
• MORTEMOUSQUE B, JACQUET A, RICHARD C, DEPONT F, COLIN J, MOORE N: Randomized double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation with Dermatophagoides pteronyssinus. Br. J. OphthalmoL (2004) 88:336–340.
   Google Scholar
• SEKIYA T,TAKAMURA E, TERAI T, OGAWA T: Safety and efficacy of topical bepotastine besilate in conjunctival allergen challenge model. International Symposium on Ocular Pharmacology and Therapeutics (2004).
   Google Scholar
• CHAPIN MJ, NICHOLS L, ONO SN et al.: Evaluation of EV131, a histamine binding protein, in a murine model of allergic conjunctivitis. Invest. OphthalmoL Vis. Sci. (ARVO 2002).
   Google Scholar
• TAKADA M, YAMADA T, NAKAHARA H, SUGIMOTO Y, IZUSHI K, KAMEI C: Experimental allergic conjunctivitis in guinea pigs induced by Japanese cedar pollen. Biol. Pharm. Bull. (2000) 23:566–569.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA T, NAKAJIMA M: Topical tranilast induced improvements of superficial punctate keratitis in two cases of allergic conjunctivitis. Japanese Journal of Clinical Ophthalmology (1998) 52:137–140.
   Google Scholar
• PAPATHANASSIOU M, GIANNOULAKI V TILIGADA E: Leukotriene antagonists attenuate late phase nitric oxide production during the hypersensitivity response in the conjunctiva. Infleimm. Res. (2004) 53:373–376.
   PubMed Web of Science ®Google Scholar
• LAMBIASE A, BONINI S, RASI G, COASSIN M, BRUSCOLINI A, BONINI S: Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch. OphthalmoL (2003) 121:615–620.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO T, IGARASHI A, HOSHINA F et al.: Effects of nonsteroidal anti-inflammatory drugs on experimental allergic conjunctivitis in Guinea pigs. OcuL PharmacoL Ther. (2003) 19:569–577.
   PubMed Web of Science ®Google Scholar
• KATO M, IMOTO K, MIYAKE H, ODA T, MIYAJI S, NAKAMURA M: Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs. J. PharmacoL Sci. (2004) 95:435–442.
   PubMed Web of Science ®Google Scholar
• BHATTACHERJEE P, MUKHOPADHYAY P, PATERSON CA, GRAFF G, GAMACHE DA, YANNI JM: AL-2512, a novel corticosteroid: preclinical assessment of anti-inflammatory and ocular hypertensive effects. J. OcuL PharmacoL Ther. (2003) 19:353–360.
   PubMed Web of Science ®Google Scholar
• KALPAXIS JG, THAYER TO: Double-blind trial of pentigetide ophthalmic solution, 0.5%, compared with cromolyn sodium, 4%, ophthalmic solution for allergic conjunctivitis. Ann. Allergy (1991) 66:393–398.
   PubMedGoogle Scholar
• BABU KS, ARSHAD SH, HOLGATE ST: Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin. Biol. Ther. (2001) 1:1049–1058.
   PubMed Web of Science ®Google Scholar
• PLEWAKO H, ARVIDSSON M, PETRUSON K et al.: The effect of omalizumab on nasal allergic inflammation. J. Allergy Clin. ImmunoL (2002) 110:68–71.
   PubMed Web of Science ®Google Scholar
• STRAUSS EC, LARSON KA, BRENNEISE I et al.: Soluble P-selectin glycoprotein ligan 1 inhibits ocular inflammation in a murine model of allergy. Invest. Ophthalmol. Vis. Sci. (1999) 40:S1336.
   PubMed Web of Science ®Google Scholar
• JOSE PJ, GRIFFITHS-JOHNSON DA, COLLINS PD et al.: Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. (1994) 179:881–887.
   PubMed Web of Science ®Google Scholar
• YING S, MENG Q, ZEIBECOGLOU K, ROBINSON DS et al.: Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. ImmunoL (1999) 163:6321–6329.
   Web of Science ®Google Scholar
• LEONARDI A, JOSE P, ZHAN, CALDER V: Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology (2003) 110:487–492.
   PubMed Web of Science ®Google Scholar
• •Role of eotaxin in ocular allergy.
   Google Scholar
• DENT G, HADJICHARALAMBOUS C, YOSHIKAWA T et al.: Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am. J. Respir. Crit. Care Med. (2004) 169:1110–1117.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, LARKIN F, IKEDA Y et al.: CAT-213, a specific monoclonal anti-eotaxin human antibody, inhibits human conjunctival mast cell activation. In: Immunology (2004). Bologna: Medimond International Proceedings (2004):527–530.
   Web of Science ®Google Scholar
• Cambridge Antibody Technology announces preliminary statement of results for the year ended 30 September 2003. Cambridge Antibody Technology Group plc. Press Release (2003).
   Google Scholar
• BENEZRA D, PE'ER J, BRODSKY M, COHEN E: Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am. j Ophthalmol. (1986) 101:278–282.
   PubMed Web of Science ®Google Scholar
• •First open clinical study on the topical use of cyclosporine for the treatment of VKC.
   Google Scholar
• SECCHI AG, TOGNON MS, LEONARDI A: Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am. j Ophthalmol. (1990) 110:137–142.
   Web of Science ®Google Scholar
• •First double-blind clinical study on the topical use of cyclosporine for the treatment of severe VKC.
   Google Scholar
• PUCCI N, NOVEMBRE E, CIANFERONI A et al.: Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann. Allergy Asthma Immunol. (2002) 89:298–303.
   PubMed Web of Science ®Google Scholar
• HINGORANI M, CALDER VI,, BUCKLEY RJ, LIGHTMAN S: The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. (1999) 40:392–399.
   PubMed Web of Science ®Google Scholar
• AKPEK EK, DART JK, WATSON S et al.: A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology (2004) 111:476–482.
   PubMed Web of Science ®Google Scholar
• ITO F, TOYOTA N, SAKAI H et al.: FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. Arch. Dermatol. Res. (1999) 291:275–283.
   PubMed Web of Science ®Google Scholar
• TOYOTA N, HASIMOTO Y, MATSUO S et al.: Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. Arch. Dermatol. Res. (1996) 288:474–480.
   PubMed Web of Science ®Google Scholar
• MATSUDA S, KOYASU S: Mechanisms of action of cyclosporin. Immunopharmacology (2000) 47:119–125.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, CHAN CC, LUYO DA, BO P, LI Q: Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest. Ophthalmol. Vis. Sci. (1996) 37:2686–2693.
   PubMed Web of Science ®Google Scholar
• AVUNDUK AM, AVUNDUK MC, ERDOL H, KAPICIOGLU Z, AKYOL N: Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica (2001) 215:290–293.
   PubMed Web of Science ®Google Scholar
• LEONARDI A, DEFRANCHIS G, FREGONA IA et al.: Effects of cyclosporin A on human conjunctival fibroblasts. Arch. Ophthalmol. (2001) 119:1512–1517.
   PubMed Web of Science ®Google Scholar
• FRANKEL D: Tacrolimus of benefit in atopic dermatitis. Lancet (1998) 352:1603.
   PubMedGoogle Scholar
• RIKKERS SM, HOLLAND GN, DRAYTON GE, MICHEL FK, TORRES MF, TAKAHASHI S: Topical tacrolimus treatment of atopic eyelid disease. Am. j Ophthalmol. (2003) 135:297–302.
   PubMed Web of Science ®Google Scholar
• SENGOKU T, SAKUMA S, SATOH S et al.: Effect of FK506 eye drops on late and delayed type response in ocular animal models. Clin. Exp. Allergy (2003) 33:1555–1560.
   PubMed Web of Science ®Google Scholar
• VICHYANOND P, TANTIMONGKOLSUK C, DUMRONGKIGCHAIPORN P, JIRAPONGSANANURUK O, VISITSUNTHORN N, KOSRIRUKVONGS P: Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J. Allergy Clin. Immunol. (2004) 113:355–358.
   PubMed Web of Science ®Google Scholar
• •First open study on the topical use of FK-506 for the treatment of severe VKC.
   Google Scholar
• RAY NF, BARANIUK JN, THAMER M et al.: Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J. Allergy Clin. Immunol. (1999) 103:401–407.
   PubMed Web of Science ®Google Scholar
• IKEDA H, TSUKAMOTO H, SATO E, MISHIMA HK, KIHIRA K: Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. Ophthalmic Epidemiol. (2004) 11:35–42.
   PubMed Web of Science ®Google Scholar
• PITT AD, SMITH AF, LINDSELL L, VOON LW, ROSE PW, BRON AJ: Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. (2004) 11:17–33.
   PubMed Web of Science ®Google Scholar